ASRT:NSD-Assertio Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 1.52

Change

+0.16 (+11.76)%

Market Cap

USD 0.06B

Volume

0.76M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Assertio Holdings Inc (ASRT) Stock Analysis:
Based on the Assertio Holdings Inc stock forecasts from 0 analysts, the average analyst target price for Assertio Holdings Inc is not available over the next 12 months. Assertio Holdings Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Assertio Holdings Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Assertio Holdings Inc’s stock price was USD 1.52. Assertio Holdings Inc’s stock price has changed by +0.10 % over the past week, +0.00 % over the past month and -12.20 % over the last year.

About

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

+1.56 (+1.93%)

USD7.56B 17.76 37.27
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
TLRY Tilray Inc

+0.29 (+3.17%)

USD4.15B N/A N/A
CGC Canopy Growth Corporation

+0.49 (+4.83%)

USD3.95B N/A N/A
ITCI Intra-Cellular Therapies Inc

+2.51 (+7.13%)

USD2.96B N/A N/A
PCRX Pacira BioSciences Inc

+2.70 (+4.99%)

USD2.34B 39.87 18.10
IRWD Ironwood Pharmaceuticals Inc

+0.25 (+2.23%)

USD1.80B 3.45 7.33
CRON Cronos Group Inc

+0.19 (+4.40%)

USD1.66B 37.00 N/A

ETFs Containing ASRT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.26% 69% D+ 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.26% 69% D+ 53% F
Trailing 12 Months  
Capital Gain -12.20% 53% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.20% 53% F 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -39.92% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.92% 2% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 33.41% 76% C 54% F
Risk Adjusted Return -119.49% 3% F N/A N/A
Market Capitalization 0.06B 19% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.00 71% C- 70% C-
Price/Book Ratio 0.65 94% A 95% A
Price / Cash Flow Ratio -0.93 26% F 56% F
EV/EBITDA 3.87 78% C+ 83% B
Management Effectiveness  
Return on Equity -35.00% 60% D- 34% F
Return on Invested Capital -10.77% 66% D 33% F
Return on Assets 1.07% 76% C 54% F
Debt to Equity Ratio 129.99% 18% F 16% F
Technical Ratios  
Short Ratio 0.61 87% B+ 83% B
Short Percent 2.81% 71% C- 48% F
Beta 1.53 31% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector